EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Kaiyan Chen iD, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu iD, Wei Hong iD, Hui Li, Xiaoling Xu, Hongyang Lu iD, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6548 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2023. Verfasst von Kaiyan Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR ‐mutated NSCLC. This study aimed to investigate the efficacy and safety of PD‐1 blockade with sintilimab plus anti‐angiogenic treatment with anlotinib in patients with NSCLC harboring uncommon EGFR mutations.

Methods

Patients with metastatic NSCLC harboring uncommon EGFR mutations after two previous treatments, including a platinum‐based chemotherapy regimen and a targeted treatment (or chemotherapy only for patients harboring EGFR ex20ins), received sintilimab combined with anlotinib. The primary endpoint was objective response rate (ORR).

Results

At data cutoff (September 27, 2022), median follow‐up was 22.3 months (range, 1.2–37.6). Among 21 enrolled patients, 12 had EGFR ex20ins and nine had other uncommon EGFR mutations such as L861Q, G719A, and G709X. Overall, eight patients (38.1%) achieved an objective response, and 18 (85.7%) achieved disease control. Median (95% CI) progression‐free survival (PFS) was 7.0 (5.4–8.6) months, and median overall survival (OS) was 20.0 (15.6–24.4) months. The 12‐month PFS rate (95% CI) was 22.2% (7.4–42.0), and the 12‐month OS rate was 66.7% (42.5–82.5). Patients harboring EGFR ex20ins had similar ORR and PFS to those with other mutations. Six patients (28.6%) experienced grade 3 treatment‐related adverse events (TRAEs); hand‐foot syndrome was the most common grade 3 TRAE (2 patients; 9.5%). No grade ≥4 TRAEs were observed.

Conclusions

The combination of sintilimab and anlotinib demonstrated durable efficacy and was generally well tolerated in patients with NSCLC and uncommon EGFR mutations who had received prior standard‐of‐care treatments. ( ClinicalTrials.gov identifier: NCT04790409).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansProspective StudiesMutationErbB ReceptorsAntibodies, Monoclonal, HumanizedIndolesQuinolines

Stichwörter der Autor:innen

PD-1anlotinibanti-angiogenicnon-small cell lung cancer (NSCLC)sintilimabuncommon EGFR mutations

Substanzen

ErbB ReceptorssintilimabAntibodies, Monoclonal, HumanizedanlotinibIndolesQuinolines

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  • Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China.
  • Department of Radiotherapy and Chemotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
  • Department of Respiratory and Critical Care Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China.

ORCID-Profile: Kaiyan Chen, Xiaoqing Yu, Wei Hong, Hongyang Lu, Yun Fan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, K., Xu, Y., Huang, Z., Yu, X., Hong, W., Li, H., Xu, X., Lu, H., Xie, F., Chen, J., Xu, Y., & Fan, Y. (2023). Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial. Cancer Medicine. https://doi.org/10.1002/cam4.6548

Vancouver

Chen K, Xu Y, Huang Z, Yu X, Hong W, Li H, et al. Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial. Cancer Medicine. 2023. doi:10.1002/cam4.6548

BibTeX
@article{Chen2023,
  author = {Chen, Kaiyan and Xu, Yanjun and Huang, Zhiyu and Yu, Xiaoqing and Hong, Wei and Li, Hui and Xu, Xiaoling and Lu, Hongyang and Xie, Fajun and Chen, Jun and Xu, Youzu and Fan, Yun},
  title = {Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6548}
}
Kostenlos starten →